لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Schiantarelli J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA., Pappa T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA.; Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, MA., Conway J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA.; Department of Biomedical Informatics, Harvard Medical School, Boston, MA., Crowdis J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA., Reardon B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA., Dietlein F; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA., Huang J; Yale School of Medicine, New Haven, CT., Stanizzi D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Carey E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Bosma-Moody A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA., Imamovic A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA., Han S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA.; Department of Biological and Biomedical Sciences, Harvard Medical School, Boston, MA., Camp S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA., Kofman E; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA., Shannon E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA., Barletta JA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., He MX; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA.; Harvard Graduate Program in Biophysics, Boston, MA., Liu D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA., Park J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA., Lorch JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA.

المصدر: JCO precision oncology [JCO Precis Oncol] 2022 Aug; Vol. 6, pp. e2200183.

نوع المنشور: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Ovarian Neoplasms*/drug therapy , Thyroid Neoplasms*/drug therapy, Carboplatin/therapeutic use ; Female ; Humans ; Platinum/therapeutic use

المؤلفون: Wan Z; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Zhong AX; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Zhang S; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Pavlou G; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Coughlin MF; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Shelton SE; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Nguyen HT; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Lorch JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Kamm RD; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.; Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.

المصدر: Small methods [Small Methods] 2022 Jun; Vol. 6 (6), pp. e2200143. Date of Electronic Publication: 2022 Apr 03.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: WILEY-VCH Verlag GmbH & Co. KGaA Country of Publication: Germany NLM ID: 101724536 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2366-9608 (Electronic) Linking ISSN: 23669608 NLM ISO Abbreviation: Small Methods Subsets: MEDLINE

مواضيع طبية MeSH: Microvessels* , Neovascularization, Physiologic*/physiology, Lab-On-A-Chip Devices

المؤلفون: Tyan K; Harvard Medical School, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, Massachusetts, USA., Bae JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Lorch JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Margalit DN; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, Massachusetts, USA., Tishler RB; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, Massachusetts, USA., Huynh MA; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, Massachusetts, USA., Jo VY; Department of Pathology, Brigham & Women's Hospital, Boston, Massachusetts, USA., Haddad RI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Chau NG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; BC Cancer, Vancouver Center, Vancouver, British Columbia, Canada., Hanna GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Schoenfeld JD; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, Massachusetts, USA.

المصدر: Head & neck [Head Neck] 2022 Mar; Vol. 44 (3), pp. 722-734. Date of Electronic Publication: 2021 Dec 19.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: John Wiley And Sons Country of Publication: United States NLM ID: 8902541 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0347 (Electronic) Linking ISSN: 10433074 NLM ISO Abbreviation: Head Neck Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Adenoid Cystic*/diagnostic imaging , Carcinoma, Adenoid Cystic*/therapy, Humans ; Retrospective Studies ; Time-to-Treatment ; Tumor Burden

المؤلفون: Hanna GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. glenn_hanna@dfci.harvard.edu., O'Neill A; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Shin KY; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Wong K; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Jo VY; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Quinn CT; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Cutler JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Flynn M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Lizotte PH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Annino DJ Jr; Division of Otolaryngology-Head and Neck Surgery, Brigham and Women's Hospital and Head and Neck Surgical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Goguen LA; Division of Otolaryngology-Head and Neck Surgery, Brigham and Women's Hospital and Head and Neck Surgical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Kass JI; Reliant Medical Group, Worcester, Massachusetts., Rettig EM; Division of Otolaryngology-Head and Neck Surgery, Brigham and Women's Hospital and Head and Neck Surgical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Sethi RKV; Division of Otolaryngology-Head and Neck Surgery, Brigham and Women's Hospital and Head and Neck Surgical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Lorch JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Schoenfeld JD; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts., Margalit DN; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts., Tishler RB; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts., Everett PC; Department of Medical Oncology, Boston Medical Center, Boston, Massachusetts., Desai AM; Department of Hematology/Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts., Cavanaugh ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Paweletz CP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Egloff AM; Division of Otolaryngology-Head and Neck Surgery, Brigham and Women's Hospital and Head and Neck Surgical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Uppaluri R; Division of Otolaryngology-Head and Neck Surgery, Brigham and Women's Hospital and Head and Neck Surgical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Haddad RI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Feb 01; Vol. 28 (3), pp. 468-478. Date of Electronic Publication: 2021 Oct 19.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Head and Neck Neoplasms*/drug therapy , Head and Neck Neoplasms*/mortality , Head and Neck Neoplasms*/pathology , Head and Neck Neoplasms*/surgery , Immune Checkpoint Inhibitors*/administration & dosage , Neoadjuvant Therapy* , Neoplasm Recurrence, Local*/drug therapy , Nivolumab*/administration & dosage , Squamous Cell Carcinoma of Head and Neck*/drug therapy , Squamous Cell Carcinoma of Head and Neck*/mortality , Squamous Cell Carcinoma of Head and Neck*/pathology , Squamous Cell Carcinoma of Head and Neck*/surgery, Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Disease-Free Survival ; Salvage Therapy ; Treatment Outcome

المؤلفون: Mahmood U; Dana-Farber Cancer Institute, Boston, Massachusetts., Lorch JH; Dana-Farber Cancer Institute, Boston, Massachusetts.

المصدر: Cancer cytopathology [Cancer Cytopathol] 2022 Jan; Vol. 130 (1), pp. 8-11. Date of Electronic Publication: 2021 Nov 08.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 101499453 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1934-6638 (Electronic) Linking ISSN: 1934662X NLM ISO Abbreviation: Cancer Cytopathol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/therapeutic use , Thyroid Neoplasms*/drug therapy , Thyroid Neoplasms*/genetics, Humans ; Precision Medicine ; Protein Kinase Inhibitors/therapeutic use

المؤلفون: Zhao B; Department of Surgery, Brigham and Women's Hospital, Boston MA. Electronic address: https://twitter.com/@BixiaoZhao., Aggarwal A; Department of Surgery, Brigham and Women's Hospital, Boston MA., Marshall JA; Department of Surgery, Brigham and Women's Hospital, Boston MA., Barletta JA; Department of Pathology, Brigham and Women's Hospital, Boston MA., Kijewski MF; Department of Radiology, Brigham and Women's Hospital, Boston MA., Lorch JH; Head and Neck Center, Dana Farber Cancer Institute, Boston, MA. Electronic address: https://twitter.com/@DrLorch., Nehs MA; Department of Surgery, Brigham and Women's Hospital, Boston MA. Electronic address: mnehs@bwh.harvard.edu.

المصدر: Surgery [Surgery] 2022 Jan; Vol. 171 (1), pp. 227-234. Date of Electronic Publication: 2021 Jul 29.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Mosby Country of Publication: United States NLM ID: 0417347 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-7361 (Electronic) Linking ISSN: 00396060 NLM ISO Abbreviation: Surgery Subsets: MEDLINE

مواضيع طبية MeSH: Diet, Ketogenic*, Pyruvates/*pharmacology , Thyroid Carcinoma, Anaplastic/*therapy , Thyroid Neoplasms/*therapy , Warburg Effect, Oncologic/*drug effects, Animals ; Cell Line, Tumor ; Cell Proliferation ; Combined Modality Therapy/methods ; Female ; Humans ; Mice ; Pyruvates/therapeutic use ; Thyroid Carcinoma, Anaplastic/pathology ; Thyroid Neoplasms/pathology ; Tumor Burden/drug effects ; Xenograft Model Antitumor Assays

المؤلفون: Pappa T; Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Ahmadi S; Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Marqusee E; Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Johnson HL; Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Nehs MA; Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Cho NL; Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Barletta JA; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Lorch JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Doherty GM; Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Lindeman NI; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Alexander EK; Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. ilanda@bwh.harvard.edu ekalexander@bwh.harvard.edu.; Harvard Medical School, Boston, Massachusetts., Landa I; Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. ilanda@bwh.harvard.edu ekalexander@bwh.harvard.edu.; Harvard Medical School, Boston, Massachusetts.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Aug 01; Vol. 27 (15), pp. 4256-4264. Date of Electronic Publication: 2021 Jun 04.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Mutation*, Phosphatidylinositol 3-Kinases/*physiology , Proto-Oncogene Proteins B-raf/*genetics , Proto-Oncogene Proteins c-akt/*physiology , TOR Serine-Threonine Kinases/*physiology , Thyroid Cancer, Papillary/*genetics , Thyroid Neoplasms/*genetics, Adult ; Female ; Humans ; Male ; Middle Aged ; Prognosis ; Signal Transduction/physiology

المؤلفون: Hanna GJ; Department of Medical Oncology, Center for Head & Neck Oncology, Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, Boston, USA. Electronic address: glenn_hanna@dfci.harvard.edu., ONeill A; Department of Data Science, Dana-Farber Cancer Institute, Boston, USA., Cutler JM; Department of Medical Oncology, Center for Head & Neck Oncology, Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, Boston, USA., Flynn M; Department of Medical Oncology, Center for Head & Neck Oncology, Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, Boston, USA., Vijaykumar T; Center for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, USA., Clark JR; Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, USA., Wirth LJ; Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, USA., Lorch JH; Department of Medical Oncology, Center for Head & Neck Oncology, Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, Boston, USA., Park JC; Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, USA., Mito JK; Department of Pathology, Brigham & Women's Hospital, Boston, USA., Lohr JG; Center for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, USA., Kaufman J; Adenoid Cystic Carcinoma Research Foundation, USA., Burr NS; Adenoid Cystic Carcinoma Research Foundation, USA., Zon LI; Department of Stem Cell and Regenerative Biology, Boston Children's Hospital and Harvard Medical School, Boston, USA., Haddad RI; Department of Medical Oncology, Center for Head & Neck Oncology, Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, Boston, USA.

المصدر: Oral oncology [Oral Oncol] 2021 Aug; Vol. 119, pp. 105366. Date of Electronic Publication: 2021 Jun 03.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9709118 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0593 (Electronic) Linking ISSN: 13688375 NLM ISO Abbreviation: Oral Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Adenoid Cystic*/drug therapy, Tretinoin/*therapeutic use, Antineoplastic Combined Chemotherapy Protocols ; Humans ; Neoplasm Recurrence, Local/drug therapy ; Phosphatidylinositol 3-Kinases ; Treatment Outcome